Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty-two–week open-label trial-Reference-Cited by-同舟云学术

Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty-two–week open-label trial

Published:2006 Issue:2 Volume:54 Page:678-681
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis Rheum

Author:

Haibel Hildrun,Rudwaleit Martin,Brandt Henning C.,Grozdanovic Zarho,Listing Joachim,Kupper Hartmut,Braun Jürgen,Sieper Joachim

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Reference18 articles.

1. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors

2. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

3. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial

4. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis

5. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis

Cited by 134 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-protein phosphatase magnesium-dependent 1A-IgM levels in patients with active ankylosing spondylitis: a potential biomarker;Advances in Rheumatology;2024-09-13

2. Bechterew’s Syndrome;Genetic Syndromes;2023-12-06

3. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies;Annals of the Rheumatic Diseases;2023-10-04

4. Seronegative spondyloarthropathy-associated inflammatory bowel disease;World Journal of Gastroenterology;2023-01-21

5. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials;Annals of the Rheumatic Diseases;2023-01-17